Autolus Therapeutics Q3 2026 net loss narrows 30% year over year to $55.09 million

By Public Technologies
  • Autolus Therapeutics’ third-quarter 2026 net loss narrowed 30% year-over-year to $55.1 million.
  • AUCATZYL net product revenue jumped 95% year-over-year to $41.2 million, driven primarily by increasing demand.
  • Gross margin rose to 57% from 55% in the second quarter, supported by manufacturing efficiencies.
  • Initial progressive multiple sclerosis trial data were postponed to October 2027 to allow longer follow-up.
  • Full-year 2026 AUCATZYL net product revenue is now expected to reach or exceed the prior guidance’s $150 million upper end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9873899) on November 10, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.